Atopic Dermatitis

At the RAD 2022 Conference, Steve Xu, MD, MSc, explains how a wearable sensor can better track the progression of atopic dermatitis while a patient is sleeping.

Jonathan Silverberg, MD, PhD, MPHS, gives an overview of topical therapies for atopic dermatitis at the 2022 virtual RAD conference.

At the 2022 RAD virtual conference, a dermatologist examines treatment options for AD in various racial and ethnic groups.

A 2022 RAD Conference abstract presentation showed the epidemiology of type 2 associated conditions included in patients with AD.

At the 2022 RAD Conference, a Harvard University psychologist discusses ways that practitioners can help identify and treat children with adverse mental health outcomes as a result of atopic dermatitis.

A 2022 RAD Conference poster presentation explores the efficacy of the therapy for the treatment or prevention of AD.

A 2022 RAD Conference poster presentation explored how to better support caregivers of children with atopic dermatitis.

A poster presentation from the 2022 RAD Conference analyzed manifestations of atopic dermatitis across racial groups.

Raj Chovatiya, MD, PhD, gives a preview of his discussions on topical formulations of atopic dermatitis and advancing therapeutic expectations at this weekend’s RAD conference.

Korey Capozza, MPH, Executive Director of Global Parents for Eczema Research, shares what she is looking forward to at the Revolutionizing Atopic Dermatitis virtual conference.

Jonathan Silverberg, MD, PHD, MPHS, talks about the exciting highlights of the Revolutionizing Atopic Dermatitis virtual conference on December 11.

New Clinical Trial Evidence Does Not Support Dairy Avoidance as a Beneficial Treatment for Pediatric AD.

Raj Chovatiya, MD, PhD, and Lisa Swanson, MD, FAAD, explore the impact of recent advances in atopic dermatitis treatment and look to future possibilities.

Raj Chovatiya, MD, PhD, and Lisa Swanson, MD, FAAD, review the challenges of identifying the right regimens for patients and the many factors that influence treatment selection.

Raj Chovatiya, MD, PhD, and Lisa Swanson, MD, FAAD, discuss how to talk about safety concerns with patients.

The author of a new study on JAK inhibitors discusses his surprising findings on the safety profiles of these new medications for dermatologic conditions.

Experts discuss game-changing drugs and what’s in the pipeline.

Experts share clinical insights boxed warning for the JAK inhibitor drug class.

Raj Chovatiya, MD, PhD, and Lisa Swanson, MD, FAAD, explore the burden of itch in atopic dermatitis, and why JAK inhibitors may be able to provide relief.

In this episode, Bernard Cohen, MD, professor of pediatrics and dermatology at Johns Hopkins University School of Medicine, talks about how physicians and patients should treat atopic dermatitis in the winter months, and some new data on treating newborns.

Dermavant announced positive results from its pediatric maximal usage study.

BLA submission is based on phase 3 trial results evaluating the safety and efficacy of lebrikizumab.

Brexogen Inc.’s exosome therapy is the first entry of a clinical trial of exosome treatment for atopic dermatitis.

Raj Chovatiya, MD, PhD, and Lisa Swanson, MD, FAAD, talk about the use of oral systemic agents and what they’ve learned about the patient experience from the use of these agents.

Raj Chovatiya, MD, PhD, and Lisa Swanson, MD, FAAD, examine the clinical context for the approval of topical ruxolitinib and its role in the treatment armamentarium.